Studies in mice have shown that RGS2 deletion leads to a significant inhibition of tumor processes by reducing the blood supply to the tumor as a result of angiogenesis inhibition [50,51] In studies on ovarian cancer, cells that showed low RGS2 expression were characterized by considerably greater chemotherapy resistance. This evidence concerns the gene RGS2 and neoplasm.